Adicet Bio is a biotechnology business based in the US. Adicet Bio shares (ACET) are listed on the NASDAQ and all prices are listed in US Dollars. Adicet Bio employs 143 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.51 |
|---|---|
| 52-week range | $1.05 - $3.77 |
| 50-day moving average | $1.38 |
| 200-day moving average | $1.82 |
| Wall St. target price | $9.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.94 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.51 from 2024-07-25
| 1 week (2024-07-19) | 21.77% |
|---|---|
| 1 month (2024-06-26) | 12.69% |
| 3 months (2024-04-26) | -10.12% |
| 6 months (2024-01-26) | -40.32% |
| 1 year (2023-07-26) | -40.08% |
|---|---|
| 2 years (2022-07-22) | -91.14% |
| 3 years (2021-07-26) | 7.57 |
| 5 years (2019-07-26) | 66.5 |
Valuing Adicet Bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adicet Bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adicet Bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.82. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adicet Bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Gross profit TTM | $25 million |
|---|---|
| Return on assets TTM | -27.2% |
| Return on equity TTM | -53.25% |
| Profit margin | 0% |
| Book value | $3.15 |
| Market Capitalization | $101.9 million |
TTM: trailing 12 months
We're not expecting Adicet Bio to pay a dividend over the next 12 months.
Adicet Bio's shares were split on a 1:7 basis on 15 September 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Adicet Bio shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Adicet Bio shares which in turn could have impacted Adicet Bio's share price.
Over the last 12 months, Adicet Bio's shares have ranged in value from as little as $1.05 up to $3.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adicet Bio's is 1.693. This would suggest that Adicet Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adicet Bio, Inc. , a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.